CompaniesEutilex

Eutilex

active
Seoul, Korea
Founded 2015
Website
About

T cell and antibody therapies

Areas of Focus

Categories

Biologics & BiopharmaceuticalStem Cell & Cellular TherapyAntibody
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

4

As Collaborator

0

Total Enrollment

209

By Phase

PHASE1: 2PHASE1/PHASE2: 2

By Status

RECRUITING: 3UNKNOWN: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT03789617
NCT04903873
NCT05798026
NCT05783570
Hover over trial bars to see details

Recent Trials

NCT05783570Lead Sponsor
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
PHASE1Recruiting
12 participants
Started: Aug 24, 2023 · Completed: Dec 31, 2025
NCT05798026Lead Sponsor
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
PHASE1Recruiting
15 participants
Started: Aug 8, 2023 · Completed: Dec 31, 2025
NCT04903873Lead Sponsor
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
110 participants
Started: May 31, 2021 · Completed: Dec 31, 2025
NCT03789617Lead Sponsor
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
PHASE1/PHASE2Unknown
72 participants
Started: Dec 14, 2018 · Completed: Dec 31, 2024
Locations (1)
Headquarters
Seoul, Korea
Map

Loading map...